INTRODUCTION
============

During embryonic development and cellular differentiation, distinct sets of genes are selectively expressed in cells to establish specific tissues or organs. Such highly organized molecular events are tightly regulated at the transcriptional level, and this precise spatiotemporal gene regulation is essential for normal development ([@b16-molce-41-6-506]; [@b30-molce-41-6-506]; [@b39-molce-41-6-506]). Although the promoter region of a gene---a DNA element in close proximity to the transcriptional start site (TSS)---is sufficient for the initial assembly of the transcriptional machinery for gene transcription, this step often induces only limited or basal levels of gene expression. Gene expression levels can be dramatically increased through the cooperation between a promoter and distal regulatory regions by promoter--enhancer interactions ([@b6-molce-41-6-506]; [@b51-molce-41-6-506]). More than three decades ago, the first enhancer element was identified as a short DNA sequence in the SV40 virus genome, which could enhance expression of the β-globin gene in HeLa cells by several orders of magnitude ([@b4-molce-41-6-506]). Since then, many enhancers have been identified in both prokaryotes and eukaryotes, and their biochemical and physiological functions have been extensively studied ([@b5-molce-41-6-506]; [@b26-molce-41-6-506]).

Several hallmarks of active enhancer regions have been identified, which can be used for the prediction of putative enhancers in the mammalian genome ([@b14-molce-41-6-506]; [@b49-molce-41-6-506]). Prior to the adoption of various genome-wide analysis tools, only the short enhancer elements in the local DNA region could be identified and studied. However, through the integration of chromatin immunoprecipitation and next-generation sequencing technology (ChIP-seq), whole-genomic landscapes of regulatory elements controlling specific gene sets can now be thoroughly explored. This approach led to the discovery of a new class of enhancers known as super-enhancers, which covers the extremely long region of regulatory DNA and are closely associated to cell identity genes ([@b17-molce-41-6-506]; [@b54-molce-41-6-506]). In this review, I focus on the available tools for identifying super-enhancers, as well as their chromatin structures and compositions, and summarize the compelling evidence revealing the biological functions of super-enhancers in determining cellular identity. I further highlight the physical alteration of super-enhancers during tumorigenesis and at the onset of other complex diseases and discuss targeting of super-enhancers for treatment and as useful biomarkers for disease diagnosis.

IDENTIFICATION OF SUPER-ENHANCERS
=================================

Enhancers have been extensively studied since the 1980s as distal regulatory elements controlling the expression of specific genes in cooperation with a proximal promoter ([@b31-molce-41-6-506]; [@b38-molce-41-6-506]; [@b49-molce-41-6-506]). There are three key characteristics used to identify an enhancer region. First, active enhancers are found in open chromatin regions devoid of nucleosomes, which allows for binding of the transcriptional machinery, including RNA polymerase, transcription factors, and co-activators. Second, active enhancer regions are typically enriched with a posttranslational modification histone mark such as monomethylation at H3 lysine 4 (H3K4me1) and acetylation at H3 lysine 27 (H3K27ac). Finally, putative enhancer regions often contain conserved DNA sequences for binding to specific transcription factors. The identification of super-enhancers shifted the focus onto the regulation of cell type-specific genes. Super-enhancers were initially identified in embryonic stem cells in 2013 ([@b17-molce-41-6-506]; [@b54-molce-41-6-506]). In the same year, a similar concept was put forward through the identification of so-called "stretch enhancers" that harbor significant risk variants associated with type II diabetes ([@b40-molce-41-6-506]). Subsequent studies revealed several cell type-specific super-enhancers in a broad spectrum of different cell types, including immune cells, chondrocytes, hair follicle cells, and mammary epithelium ([@b2-molce-41-6-506]; [@b48-molce-41-6-506]; [@b50-molce-41-6-506]; [@b52-molce-41-6-506]). Super-enhancers show several distinct features compared to typical enhancers ([Fig. 1A](#f1-molce-41-6-506){ref-type="fig"}). Unlike typical enhancers, super-enhancers comprise a set of enhancers that span across a long range of genomic DNA (\> 10 kb). Each constituent enhancer is densely occupied by lineage-specific or master transcription factors, mediators, and histone marks. Notably, these clusters of enhancers are closely associated with genes that determine the specific cell type. Several studies have also shown that enhancer RNAs (eRNAs) are associated with super-enhancer regions ([@b25-molce-41-6-506]; [@b33-molce-41-6-506]; [@b42-molce-41-6-506]). eRNAs are a class of non-coding RNAs transcribed from the DNA sequence of enhancer regions and play an active role in the transcription of nearby genes, potentially by facilitating enhancer--promoter interactions ([@b24-molce-41-6-506]). Super-enhancers are frequently insulated by CCCTC-binding factor-binding sites, suggesting that their activity may be limited by boundary elements ([@b10-molce-41-6-506]; [@b29-molce-41-6-506]; [@b55-molce-41-6-506]).

Super-enhancers are typically isolated using the Rank Ordering of Super-enhancer (ROSE) algorithm by analyzing ChIP-seq binding patterns of active enhancer marks such as H3K27ac, mediator complex subunit 1 (MED1), and lineage-specific or master transcription factors ([@b54-molce-41-6-506]). MED1 is a subunit of the mediator complex that functions as a co-activator to drive RNA polymerase II-dependent transcription by promoting the looping of enhancer to transcription start sites ([@b21-molce-41-6-506]; [@b58-molce-41-6-506]). Initial studies often focused on only one or two of these factors to identify super-enhancers. However, employing a greater number of indicators simultaneously can result in a robust set of super-enhancers that are highly correlated to cell type-specific genes ([@b48-molce-41-6-506]) ([Fig. 1B](#f1-molce-41-6-506){ref-type="fig"}). To further confirm the genomic features of super-enhancers, the chromatin accessibility of candidate regions can be examined by a DNase I hypersensitive assay. Subsequent super-enhancer candidates can then be annotated based on the nearest gene, and the gene expression levels can be examined using RNA-seq to determine correlations with high levels of cell type-specific genes in comparison to lone enhancers. With this approach, the complete chromatin landscape of super-enhancers can be mapped in the mammalian genome.

FUNCTIONAL ROLES OF SUPER-ENHANCERS
===================================

Several studies have shown that even an ectopic fragment of a super-enhancer is capable of inducing high levels of reporter gene expression compared to a typical enhancer *in vitro* ([@b2-molce-41-6-506]; [@b34-molce-41-6-506]). Although the activity of super-enhancers was clearly demonstrated using reporter assays *in vitro* and super-enhancers are frequently found near genes controlling cell identity, there has been general skepticism related to their precise biological functions given the lack of compelling *in vivo* animal studies ([@b44-molce-41-6-506]). Indeed, although several recent studies have shown that deletion or mutations of super-enhancers in specific cell lines could reduce the expression levels of cell type-specific genes ([@b18-molce-41-6-506]; [@b32-molce-41-6-506]), this phenomenon might not fully represent the *in vivo* function of super-enhancers in animal models ([@b13-molce-41-6-506]; [@b48-molce-41-6-506]) ([Table 1](#t1-molce-41-6-506){ref-type="table"}). With progress in genome editing technology, it has now become feasible to delete or mutate specific super-enhancer regions and examine their *in vivo* biological functions in the mouse genome. Recently, [@b48-molce-41-6-506] identified 440 mammary-specific super-enhancers through ChIP-seq analyses in the mouse genome, and the *in vivo* function of one of mammary-specific super-enhancers, the *Wap* super-enhancer, has been interrogated using CRISPR/Cas9 genome editing technology. *Wap* is a major milk-producing gene in mice and regulated by a super-enhancer constituted with three individual enhancers, which exists upstream of this gene in the mouse genome. Using CRISPR/Cas9 genome editing, small deletions or mutations were generated in individual or in all three constituent enhancers of the mammary-specific *Wap* super-enhancer of the mouse genome. Disruption of all three constituent enhancers dramatically reduced the expression levels of mammary-specific *Wap* genes by \~99%, indicating that isolated super-enhancers do indeed function in the regulation of mammary-specific genes *in vivo*.

Super-enhancers are also highly sensitive to external environmental cues such as lineage-determining or cell differentiation signals ([@b2-molce-41-6-506]; [@b48-molce-41-6-506]). Moreover, mutational analyses of individual and combined mutations of three constituent *Wap* super-enhancers revealed a hierarchy in their functions. The most distal enhancer plays a key role in regulating the expression of a mammary-specific *Wap* gene ([@b48-molce-41-6-506]). However, individual constituent super-enhancers in erythroid cells showed independent functions without any hierarchy, indicating that the constituent enhancers function differently in different cell types or under different environments ([@b13-molce-41-6-506]).

SUPER-ENHANCERS IN CANCERS AND OTHER COMPLEX DISEASES
=====================================================

Transcriptional deregulation caused by genetic or epigenetic changes often leads to cancer formation and the establishment of complex diseases. Thus, aberrant super-enhancers consequently result in the abnormal transcription of genes that lead to malignancies.

Super-enhancers in cancer development
-------------------------------------

Oncogenic super-enhancers were first identified in multiple myeloma cells, showing a high density of MED1 and bromodomain-containing protein 4 (BRD4) bindings ([@b34-molce-41-6-506]). BRD4 is a member of the BET family proteins, which include BRD2, BRD3, BRD4, and BRDT ([@b60-molce-41-6-506]). BET family proteins commonly contain two bromodomains that can recognize acetylated histones, bind to mediator complexes, and participate in the regulation of transcriptional elongation through interactions with RNA polymerase II ([@b17-molce-41-6-506]). Several other oncogenic super-enhancers were subsequently found across a broad spectrum of cancers, including neuroblastoma, small-cell lung cancer, medulloblastoma, breast cancer, esophageal cancer, gastric cancers, and melanoma ([@b45-molce-41-6-506]). There are two main types of aberrant super-enhancers found in various cancers: those involving mutations generated in super-enhancers and those involving the acquisition of new oncogenic super-enhancers.

Single-nucleotide alterations have been frequently identified within or near super-enhancers that drive tumorigenesis ([Fig. 2A](#f2-molce-41-6-506){ref-type="fig"}). A single nucleotide polymorphism (SNP) within a super-enhancer in the first intron of *LMO1* causes differential binding of the transcription factor GATA to subsequently influence neuroblastoma susceptibility ([@b37-molce-41-6-506]). Somatic structural variants in GF1- and GF1B-coding sequences along with the nearest super-enhancer were shown to drive the oncogenic activity in a medulloblastoma mouse model ([@b36-molce-41-6-506]).

In addition to these somatic mutations within super-enhancers, *de novo* super-enhancers are often acquired via small insertions and deletions (indel), DNA translocation, focal amplification, and transcription factor overexpression, which also result in various malignancies ([Fig. 2B](#f2-molce-41-6-506){ref-type="fig"}). In T-cell acute lymphoblastic leukemia (T cell-ALL), small indels in a non-coding intergenic region of the *TAL1* oncogene introduced the binding motifs of the transcription factor MYB, resulting in the formation of a super-enhancer regulating the *TAL1* gene ([@b35-molce-41-6-506]). In multiple myeloma, translocation of 3′ IgH super-enhancers are frequently detected near the *MYC* oncogene ([@b17-molce-41-6-506]). Translocation of breakpoints near the *MYC* gene established a *de novo* super-enhancer, which is associated with poor prognosis in myeloma patients ([@b53-molce-41-6-506]). Rearrangement of 18 kb *GATA2* enhancers is commonly detected in samples of myeloid leukemia patients, and is attributed as the cause of leukemogenesis via the deregulation of two unrelated distal genes ([@b12-molce-41-6-506]). Genome-wide chromatin mapping of adenoid cystic carcinoma also revealed that the translocation of super-enhancers drives the overexpression of the oncogenic transcription factor MYB ([@b11-molce-41-6-506]).

Besides DNA rearrangements, focal amplification of enhancer elements frequently occurs in many cancer types. Tandem repeats of DNA segments have been found within the super-enhancer of the *MYC* gene in lung cancer ([@b17-molce-41-6-506]). Distal *MYC* enhancers are juxtaposed to the focal amplified region in \~3% of acute myeloid leukemia cases ([@b47-molce-41-6-506]). Two distinct focal amplifications of super-enhancers were found at the 3′ end of the *MYC* gene in lung adenocarcinoma and endometrial carcinoma cell lines, which contributed to overexpression of the *Myc* oncogene ([@b61-molce-41-6-506]).

Overexpression of transcription factors within super-enhancers is commonly found in leukemia. In T-cell ALL, overexpression of TAL1 transcription factors has been found within a super-enhancer in the *MYC* locus ([@b17-molce-41-6-506]). Patients with high ratios of active STAT5 to NF-κB or IKROS within super-enhancers also tend to show more aggressive disease phenotypes of B-cell acute lymphoblastic leukemia (B-cell ALL) ([@b22-molce-41-6-506]). Recent studies have also demonstrated that aberrant regulation of eRNAs transcribed from super-enhancers is often linked to cancer development ([@b20-molce-41-6-506]; [@b25-molce-41-6-506]; [@b33-molce-41-6-506]), suggesting the importance of eRNAs as potential targets to block oncogenesis. Collectively, this evidence suggests that improper super-enhancer formation and alteration lead to abnormal gene regulation to generate various malignancies.

Super-enhancers in immune diseases, diabetes, and neurodegenerative diseases
----------------------------------------------------------------------------

Super-enhancers have also been associated with the progression of non-cancerous diseases, including certain autoimmune diseases, diabetes, and neurodegenerative diseases. Similar to oncogenic super-enhancers, disease-associated SNPs are frequently enriched in super-enhancers, and the subsequent gene deregulation leads to disease development.

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system mistakenly attacks healthy tissues in many body parts due to the loss of immunological tolerance for self-antigens and the production of excessive amounts of autoantibodies. Among the 72 SNPs linked to SLE to date, 22 are found in super-enhancer regions ([@b17-molce-41-6-506]). Other common autoimmune diseases such as rheumatoid arthritis are also associated with highly enriched SNPs in T-cell specific super-enhancers ([@b52-molce-41-6-506]). A genome-wide association study (GWAS) of patients with an autoimmune skin disease or vitiligo identified three SNPs only 47 bp apart in a super-enhancer region between the *HLA-DRB1* and *HLA-DQA1* genes ([@b7-molce-41-6-506]). Disease-associated super-enhancers were also found in primary T cells obtained from patients with juvenile idiopathic arthritis (JIA), which is characterized by the early onset of multifactorial autoimmune disease ([@b41-molce-41-6-506]).

Type 1 diabetes is caused by the T cell-mediated autoimmune destruction of insulin-producing β cells in the pancreas. Among 76 SNPs linked to type 1 diabetes, 13 occur in super-enhancers in primary T helper cells ([@b17-molce-41-6-506]). Integrative analyses of GWAS variants in type 2 diabetes and the epigenomic profiles of the skeletal muscles of patients with type 2 diabetes revealed that the disease risk variants significantly overlapped with stretch enhancers ([@b40-molce-41-6-506]).

Disease-specific super-enhancers are also frequently found in several neurodegenerative diseases. Among the 27 SNPs linked to Alzheimer's disease, 5 occur in the super-enhancers of the brain tissue ([@b17-molce-41-6-506]). Down-regulation of neuronal genes in a mouse model of Huntington disease resulted from the selective decrease of H3K27ac marks in super-enhancers ([@b1-molce-41-6-506]; [@b28-molce-41-6-506]).

APPLICATION OF SUPER-ENHANCERS TO CLINICAL THERAPEUTICS DEVELOPMENT
===================================================================

Collectively, the findings summarized above suggest that super-enhancers play a critical role in the regulation of genes responsible for cancer progression and the development of other complex diseases. Accordingly, there have been many attempts to use super-enhancer profiles for disease diagnosis and to design clinical therapeutics targeting super-enhancers, including small-molecule inhibitors against super-enhancer binding proteins and gene therapy strategies.

Small-molecule inhibitors
-------------------------

High-throughput screening of small-molecule inhibitors against a specific component of super-enhancers has revealed potential drug candidates. Several potent small-molecule inhibitors are already in phase I/II clinical trials to validate their pharmacological efficacy and safety ([Table 2](#t2-molce-41-6-506){ref-type="table"}).

The most extensively studied small-molecule inhibitor against super-enhancer complexes associated with multiple diseases is an inhibitor of the BET bromodomain. In particular, BRD4 is well known to interact with MED1 as a co-activator within disease-associated super-enhancers, and several types of inhibitors targeting BRD4 are currently under clinical investigations, including iBET762, OTX015, and CPI0610. The first study to demonstrate the effect of a BET inhibitor in abrogating super-enhancers was performed in multiple myeloma cells ([@b34-molce-41-6-506]). Treatment of the BET-bromodomain inhibitor JQ1 to myeloma cells led to the selective loss of BRD4 at super-enhancers and revealed the transcriptional defect of super-enhancer-associated genes such as the oncogenic *MYC* gene. Based on these findings, the ability of a BET inhibitor in the preferential disruption of super-enhancer functions was subsequently examined in other various diseases. RNA-sequencing of T cells obtained from the autoinflammation skin of patients with JIA revealed that the BET inhibitor JQ1 preferentially reduced the expression levels of disease-associated genes by selectively disrupting immune-related super-enhancers ([@b41-molce-41-6-506]). JQ1 could also sufficiently collapse super-enhancers through inhibition of BRD4 and deregulation of *MYB* transcription. These effects consequently slowed tumor growth in low-grade adenoid cystic carcinoma xenograft mice ([@b11-molce-41-6-506]). Depletion of BRD4 occupancy at c-Myc super-enhancers by JQ1 also significantly reduced the expression level of the proto-oncogene *c-Myc* in Merkel cell carcinoma mouse models ([@b46-molce-41-6-506]). JQ1 was also shown to suppress tumor cell growth by deregulating aldehyde dehydrogenase activity through inhibiting eRNAs within BRD4-regulated super-enhancers in ovarian cancer cells ([@b59-molce-41-6-506]).

Another BRD4-targeting BET inhibitor, I-BET151, was also found to downregulate super-enhancer-associated genes in acute myeloid leukemia ([@b43-molce-41-6-506]). Oral administration of I-BET726 to neuroblastoma mouse xenograft models showed clear tumor growth inhibition and reduced the expression levels of *Mycn* and *Bcl2* ([@b57-molce-41-6-506]). OTX015 is another BET inhibitor targeting BRD2, BRD3, and BRD4, which potently blocks the proliferation of cells both *in vitro* and *in vivo* in various hematological malignancies and solid tumors. The clinical potential of OTX015 in leukemia, lymphoma myeloma, and midline NUT carcinoma has been examined in a phase I trial ([@b3-molce-41-6-506]), and the clinical efficacy and safety profiles of OTX015 in glioblastoma were investigated in a phase II trial. The potential therapeutic efficacy of OTX015 was also evaluated in MYCN-driven neuroblastoma mouse models ([@b15-molce-41-6-506]).

Discovery of small-molecule inhibitors of cyclin-dependent kinases (CDKs) has provided yet another potential approach of targeting super-enhancers associated with various diseases. Transcription of specific genes requires step-wise recruitment of key regulatory and enzymatic co-factors. In particular, super-enhancer-regulated transcription is coordinated by the recruitment of BRD4, MED1, and CDK-containing transcriptional initiation/elongation complexes ([@b45-molce-41-6-506]). Thus, CDKs can be considered as another attractive target for treatment of super-enhancer-associated diseases. Through the cell-based screening of small-molecule inhibitors against CDKs, THZ1 was discovered as a covalent inhibitor of CDK7, which showed high sensitivity to RUNX-driven super-enhancers in T-cell ALL cell lines ([@b27-molce-41-6-506]). THZ1 was also found to preferentially block global *MYCN* transcriptional regulation in MYCN-amplified neuroblastoma cells ([@b8-molce-41-6-506]). Superenhancers-associated with proto-oncogenes of the MYC family were specifically susceptible to this CDK7 inhibitor in small cell lung carcinoma cells ([@b9-molce-41-6-506]). THZ-1 also showed selective inhibition of oncogenic super-enhancers in esophageal squamous cell carcinoma ([@b19-molce-41-6-506]) and in adult T-cell leukemia cells ([@b56-molce-41-6-506]). Similarly, the CDK4/6 inhibitor LEE011 selectively inhibits CDK4, down-regulates cyclin D1-associated super-enhancers, and subsequently leads to cell death in an Ewing sarcoma xenograft model ([@b23-molce-41-6-506]).

Potential gene therapeutic approaches
-------------------------------------

One of the most fundamental approaches of treating genetic or epigenetic diseases is to disrupt or correct aberrant genomic sequences responsible for the generation of disease-associated super-enhancers. With the recent advances in genome engineering technologies such as TALEN and CRISPR/Cas9, it is now more convenient to generate mutations in cells or animal models, providing unprecedented opportunities to develop effective gene therapies for superenhancer-associated diseases. For example, to directly target the enhancer mutation site in T cell leukemia cells, the CRISPR/Cas9 genome editing technique was used to generate the deletion of mutation sites spanning approximately 200 bp. Notably, deletion of the mutant allele decommissioned the chromatin features of super-enhancers at the *TAL1* locus and completely abrogated endogenous *TAL1* expression ([@b35-molce-41-6-506]). TALEN and CRISPR/Cas9 genome editing systems were also applied for the genomic excision of aberrant enhancers in acute myeloid leukemia cells. Subsequent mutations were shown to reallocate the enhancer element, suppress expression of the proto-oncogene *EVI1*, and efficiently inhibit cell growth ([@b12-molce-41-6-506]). Although the efficacy and safety of a gene therapeutic approach targeting disease-associated super-enhancers need to be further determined in various animal disease models, these new genome editing tools truly open the door to a new era for gene therapy development.

PERSPECTIVES
============

The integration of molecular biology tools with next-generation sequencing technology now provides a new opportunity to map the genomic landscape in greater detail. The recent discovery of unprecedented genome-wide enhancer subsets and identification of their unique functions in both normal development and disease progression is now a hotspot of clinical and basic research. Despite the compelling evidence of super-enhancer functions in regulating cellular identity genes, there has been scant genetic proof as to whether super-enhancers alone are sufficient to change specific cell types and determine the cell fate. Confirmation of the ability of super-enhancers to regenerate different cell types would further provide a new approach for regenerative medicine. Moreover, super-enhancers can be used as prognostic markers for the prediction of disease risk and progression. Thus, integrative analysis of a gene transcription signature and super-enhancer profile of patients or healthy individuals could emerge as an important approach for disease diagnosis. Despite massive efforts to discover small-molecule inhibitors of super-enhancers, genome editing of aberrant super-enhancers would be the most fundamental approach to cure diseases. Although it has been only four years since the CRISPR/Cas9 system was first applied to genome editing, there has been an extensive explosion in efforts to use this powerful genome editing technique for potential gene therapy. Although safety issues, including off-target effects, remain to be solved for clinical use, more advanced CRISPR/Cas9 genome engineering tools are continuously emerging, which is bringing forth a new era of gene therapy. Coupling of genome-wide super-enhancer screening with specific genome editing is expected to strengthen and establish personalized medicine in the near future.
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![Schematic diagrams of the chromatin structure of super-enhancers and an approach to identify super-enhancers\
(A) Comparison of super-enhancers and typical enhancers. In contrast to typical enhancers, super-enhancers comprise large clusters of enhancers that are densely occupied with H3K27ac, MED1, and lineage-specific or master transcription factors. (B) Simple flow chart of super-enhancer isolation steps. After non-promoter regions are extracted, super-enhancers are isolated against single factors, including H3K27ac, MED1, and lineage-specific- and master transcription factors using the ROSE algorithm. Only the overlapped super-enhancers that link to cell-type-specific genes are isolated as high-confidence super-enhancers.](molce-41-6-506f1){#f1-molce-41-6-506}

![Establishment of oncogenic super-enhancers in cancers\
(A) Mutations found in super-enhancers. (B) Newly acquired oncogenic super-enhancers by small indels, DNA translocation, focal amplification, and transcription factor overexpression.](molce-41-6-506f2){#f2-molce-41-6-506}

###### 

Representative mutational studies to determine the role of super-enhancers

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target model                       Factors for SE identification   Target gene                       Mutation tools   Deletion site/size (bp)                                                                               References
  ---------------------------------- ------------------------------- --------------------------------- ---------------- ----------------------------------------------------------------------------------------------------- -----------------------
  Mouse ES cells                     H3K27ac                         *Sox2*                            CRISPR/Cas9      13 kb in SE                                                                                           [@b32-molce-41-6-506]

  Human T-ALL\                       H3K27ac                         *TAL1*                            CRISPR/Cas9      \~200 bp in SE                                                                                        [@b35-molce-41-6-506]
  Jurkat cells                                                                                                                                                                                                                

  Human erythroid cells              H3K27ac, H3K4me1                *SLC25A37*                        CRISPR/Cas9      Three constituent enhancers                                                                           [@b18-molce-41-6-506]

  Mouse ES cells                     H3K4me1, MED12, EP300, NIPBL    *Sal1, Tet1,* and 10 more genes   CRISPR/Cas9      30 kb in *Sal1* SE, 15 kb in *Tet1* SE, and 10\~20 kb in ten different SEs                            Moorthy et al., 2017

  Mouse ES cells                     MED1, H3K27ac, H3K4me1          *Nanog*                           CRISPR/Cas9      2.5\~10.5 kb inthree different SEs                                                                    Blinka et al., 2017

  Rat vascular smooth muscle cells   H3K27ac, H3K4me1, BRD4          Fgf2, Egr2, Tgif1, Fst            CRISPR/Cas9      Four different SEs                                                                                    Das et al., 2017

  Mouse                              MED1                            *α-globin*                        Cre/LoxP         \~ 1kb in individual five constituent enhancers and with combination                                  [@b13-molce-41-6-506]

  Mouse                              H3K27ac, MED1, STAT5, GR        *Wap*                             CRISPR/Cas9      \~10 bp of specific TF binding sites in three individual constituent enhancers and with combination   [@b48-molce-41-6-506]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Examples of small-molecule inhibitors targeting super-enhancers in diseases

  Small-molecule inhibitor   Target             Disease                              Clinical phase (Clinical Trial No.)
  -------------------------- ------------------ ------------------------------------ -------------------------------------
  JQ1                        BRD4               Multiple myeloma                     
                                                Juvenile idiopathic arthritis        \-
                                                Merkel cell carcinoma                \-
                                                                                     \-
  iBET151                    BRD4               Leukemia                             \-
  iBET726                    BRD2, BRD3, BRD4   Neuroblastoma                        \-
  iBET762                    BRD2, BRD3, BRD4   NUT midline carcinoma                Phase 1 (NCT01587703)
  OTX015                     BRD2, BRD3, BRD4   Neuroblastoma                        Preclinical study
                                                Acute myeloid leukemia               Phase 1 (NCT01713582)
                                                Diffuse large B-cell lymphoma        Phase 1 (NCT01713582)
                                                Acute lymphoblastic leukemia         Phase 1 (NCT01713582)
                                                Multiple myeloma                     Phase 1 (NCT01713582)
                                                NUT midline carcinoma                Phase 1 (NCT02259114)
                                                Glioblastoma multiforme              Phase 2 (NCT02296476)
  CPI0610                    BRD4               Multiple myeloma                     Phase 1 (NCT02157636)
                                                Lymphoma                             Phase 1 (NCT01949883)
  THZ1                       CDK7               Esophageal squamous cell carcinoma   \-
                                                Neuroblastoma                        \-
                                                Adult T-cell leukemia/lymphoma       \-
                                                Small cell lung cancer               \-
  Lee011                     CDK4/6             Ewing sarcoma                        \-
